Your browser doesn't support javascript.
loading
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
Ansell, Stephen M; Flinn, Ian; Taylor, Matthew H; Sikic, Branimir I; Brody, Joshua; Nemunaitis, John; Feldman, Andrew; Hawthorne, Thomas R; Rawls, Tracey; Keler, Tibor; Yellin, Michael J.
Affiliation
  • Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Flinn I; Center for Blood Cancer, Sarah Cannon Research Institute, Nashville, TN.
  • Taylor MH; Franz Cancer Center, Providence Portland Medical Center, Portland, OR.
  • Sikic BI; Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, CA.
  • Brody J; Division of Hematology and Oncology, Mount Sinai Medical Center, New York, NY.
  • Nemunaitis J; Division of Hematology, University of Toledo College of Medicine and Life Sciences, Toledo, OH; and.
  • Feldman A; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Hawthorne TR; Celldex Therapeutics, Inc., Hampton, NJ.
  • Rawls T; Celldex Therapeutics, Inc., Hampton, NJ.
  • Keler T; Celldex Therapeutics, Inc., Hampton, NJ.
  • Yellin MJ; Celldex Therapeutics, Inc., Hampton, NJ.
Blood Adv ; 4(9): 1917-1926, 2020 05 12.
Article in En | MEDLINE | ID: mdl-32380537
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Hematologic Neoplasms Limits: Animals / Humans Language: En Journal: Blood Adv Year: 2020 Document type: Article Affiliation country: Mongolia Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Hematologic Neoplasms Limits: Animals / Humans Language: En Journal: Blood Adv Year: 2020 Document type: Article Affiliation country: Mongolia Country of publication: Estados Unidos